Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study-Reference-Cited by-同舟云学术

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

Published:2017-07 Issue:1 Volume:153 Page:77-86.e6
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Sands Bruce E.,Chen Jingjing,Feagan Brian G.,Penney Mark,Rees William A.,Danese Silvio,Higgins Peter D.R.,Newbold Paul,Faggioni Raffaella,Patra Kaushik,Li Jing,Klekotka Paul,Morehouse Chris,Pulkstenis Erik,Drappa Jörn,van der Merwe René,Gasser Robert A.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference25 articles.

1. Crohn's disease;Baumgart;Lancet,2012

2. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007

3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

4. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

5. Maintenance therapy with certolizumab pegol for Crohn's disease;Schreiber;N Engl J Med,2007

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study;Clinical Pharmacology in Drug Development;2024-09-04

2. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins;The Korean Journal of Gastroenterology;2024-08-25

3. Integration of Gut Mycobiota and Oxidative Stress to Decipher the Roles of C-Type Lectin Receptors in Inflammatory Bowel Diseases;Immunological Investigations;2024-08-08

4. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease;Antibiotics;2024-07-25

5. Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease;Frontiers in Immunology;2024-07-17